Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group

التفاصيل البيبلوغرافية
العنوان: Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group
المؤلفون: L, Chaillous, H, Lefèvre, C, Thivolet, C, Boitard, N, Lahlou, C, Atlan-Gepner, B, Bouhanick, A, Mogenet, M, Nicolino, J C, Carel, P, Lecomte, R, Maréchaud, P, Bougnères, B, Charbonnel, P, Saï
المصدر: Lancet (London, England). 356(9229)
سنة النشر: 2000
مصطلحات موضوعية: Adult, Glycated Hemoglobin, Male, Adolescent, C-Peptide, Glutamate Decarboxylase, Insulin Antibodies, Administration, Oral, Recombinant Proteins, Autoimmune Diseases, Islets of Langerhans, Diabetes Mellitus, Type 1, Humans, Insulin, Female, Child, Autoantibodies
الوصف: Oral administration of autoantigens can slow the progression of beta-cell destruction in non-obese diabetic mice. We investigated whether oral administration of recombinant human insulin could protect residual beta-cell function in recent-onset type 1 diabetes.We enrolled 131 autoantibody-positive diabetic patients aged 7-40 years within 2 weeks of diagnosis (no ketoacidosis at diagnosis, weight loss10%, polyuria for6 weeks). They were randomly assigned 2.5 mg or 7.5 mg oral insulin daily or placebo for 1 year, in addition to subcutaneous insulin therapy. Serum C-peptide concentrations were measured in the fasting state and after stimulation, to assess beta-cell function. Autoantibodies to beta-cell antigens were assayed. Analyses were by intention to treat.Baseline C-peptide and haemoglobin A1c concentrations were similar in the three groups. During follow-up, there were no differences between the groups assigned 2.5 mg or 7.5 mg oral insulin or placebo in subcutaneous insulin requirements, haemoglobin A1c concentrations, or measurements of fasting (mean at 12 months 0.18 [SD 0.17], 0.17 [0.17], and 0.17 [0.12] nmol/L) or stimulated C-peptide concentrations (glucagon-stimulated 0.39 [0.38], 0.37 [0.39], and 0.33 [0.24] nmol/L; meal-stimulated 0.72 [0.60], 0.49 [0.49], and 0.57 [0.51 nmol/L]. Neither age nor C-peptide concentration at entry influenced treatment effects. No differences were seen in the time-course or titres of antibodies to insulin, glutamic acid decarboxylase, or islet antigen 2.At the doses used in this trial, oral administration of insulin initiated at clinical onset of type 1 diabetes did not prevent the deterioration of beta-cell function.
تدمد: 0140-6736
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::a880c6cef742b9abab44b7bfe32952a2Test
https://pubmed.ncbi.nlm.nih.gov/10950225Test
رقم الانضمام: edsair.pmid..........a880c6cef742b9abab44b7bfe32952a2
قاعدة البيانات: OpenAIRE